Evaluation of molecular forms of prostate‐specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy
Open Access
- 9 September 2008
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 124 (3) , 659-663
Abstract
Most pretreatment risk‐assessment models to predict biochemical recurrence (BCR) after radical prostatectomy (RP) for prostate cancer rely on total prostate‐specific antigen (PSA), clinical stage, and biopsy Gleason grade. We investigated whether free PSA (fPSA) and human glandular kallikrein‐2 (hK2) would enhance the predictive accuracy of this standard model. Preoperative serum samples and complete clinical data were available for 1,356 patients who underwent RP for localized prostate cancer from 1993 to 2005. A case‐control design was used, and conditional logistic regression models were used to evaluate the association between preoperative predictors and BCR after RP. We constructed multivariable models with fPSA and hK2 as additional preoperative predictors to the base model. Predictive accuracy was assessed with the area under the ROC curve (AUC). There were 146 BCR cases; the median follow up for patients without BCR was 3.2 years. Overall, 436 controls were matched to 146 BCR cases. The AUC of the base model was 0.786 in the entire cohort; adding fPSA and hK2 to this model enhanced the AUC to 0.798 (p = 0.053), an effect largely driven by fPSA. In the subgroup of men with total PSA ≤10 ng/ml (48% of cases), adding fPSA and hK2 enhanced the AUC of the base model to a similar degree (from 0.720 to 0.726, p = 0.2). fPSA is routinely measured during prostate cancer detection. We suggest that the role of fPSA in aiding preoperative prediction should be investigated in further cohorts.Keywords
This publication has 27 references indexed in Scilit:
- Long-Term Prediction of Prostate Cancer Up to 25 Years Before Diagnosis of Prostate Cancer Using Prostate Kallikreins Measured at Age 44 to 50 YearsJournal of Clinical Oncology, 2007
- Comparison of Free and Total Forms of Serum Human Kallikrein 2 and Prostate-Specific Antigen for Prediction of Locally Advanced and Recurrent Prostate CancerClinical Chemistry, 2007
- Reproducibility and Accuracy of Measurements of Free and Total Prostate-Specific Antigen in Serum vs Plasma after Long-Term Storage at −20 °CClinical Chemistry, 2006
- Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA‐elevation in serumInternational Journal of Cancer, 2005
- Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with ageThe Prostate, 2005
- Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissueThe Prostate, 2004
- Development of Sensitive Immunoassays for Free and Total Human Glandular Kallikrein 2Clinical Chemistry, 2004
- The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancerThe Prostate, 2002
- PREOPERATIVE SERUM PROSTATE SPECIFIC ANTIGEN LEVELS BETWEEN 2 AND 22 NG./ML. CORRELATE POORLY WITH POST-RADICAL PROSTATECTOMY CANCER MORPHOLOGY: PROSTATE SPECIFIC ANTIGEN CURE RATES APPEAR CONSTANT BETWEEN 2 AND 9 NG./ML.Journal of Urology, 2002
- Zonal Distribution of Prostatic AdenocarcinomaAmerican Journal of Surgical Pathology, 1988